Fedratinib
|
|
|
- CAS-Nr.
- 936091-26-8
- Englisch Name:
- Fedratinib
- Synonyma:
- CS-57;TG-101348;SAR-302503;Fedratinib;Fedratinib D9;TG101348, >=98%;2H9]-Fedratinib;SAR302503/TG101348;TG101348/TG-101348;Fedratinib/TG101384
- CBNumber:
- CB12485002
- Summenformel:
- C27H36N6O3S
- Molgewicht:
- 524.68
- MOL-Datei:
- 936091-26-8.mol
|
Fedratinib Eigenschaften
- Schmelzpunkt:
- 180-182°C
- Siedepunkt:
- 713.7±70.0 °C(Predicted)
- Dichte
- 1.247
- storage temp.
- Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
- L?slichkeit
- DMSO (Slightly), Methanol (Slightly)
- Aggregatzustand
- Beige powder.
- pka
- 11.95±0.50(Predicted)
- Farbe
- White to Off-White
- CAS Datenbank
- 936091-26-8
Fedratinib Chemische Eigenschaften,Einsatz,Produktion Methoden
Charakteristisch
Class: non-receptor tyrosine kinase
Treatment: myeloproliferative diseases
Oral bioavailability = 18–37%
Elimination half-life = 2–3 days
Protein binding = 91–96%
Verwenden
A potent, highly selective and ATP-competitive JAK2 inhibitor with an IC50 of 3 nM for JAK2 and JAK2V617F.
Fedratinib Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Fedratinib Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 171)Lieferanten
936091-26-8()Verwandte Suche:
- N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide
- TG-101348
- N-TERT-BUTYL-3-(5-METHYL-2-(4-(2-(PYRROLIDIN-1-YL)ETHOXY)PHENYLAMINO)PYRIMIDIN-4-YLAMINO)BENZENESULFONAMIDE
- SAR-302503
- BenzenesulfonaMide, N-(1,1-diMethylethyl)-3-[[5-Methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]aMino]-4-pyriMidinyl]aMino]-
- TG101348 (SAR302503)
- TG101348/TG-101348
- SAR302503/TG101348
- Fedratinib (SAR302503, TG101348)
- N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide TG 101348
- Fedratinib (TG101348)
- Fedratinib
- TG101348, >=98%
- Fedratinib/TG101384
- FEDRATINIB (SAR302503, TG101348);TG101348;TG 101348
- N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl
- TG101348; TG 101348; TG-101348; SAR302503; SAR-302503; SAR 302503; FEDRATINIB.
- TG101348(Fedratinib)
- CS-57
- TG-101348; TG 101348;SAR-302503;SAR 302503;SAR302503
- TG 101348 - Fedratinib | SAR 302503
- Fedratinib (SAR302503, TG101348), ≥98%
- Fedratinib (SAR302503)
- Fedratinib(TG101348,SAR302503)
- FEDRATINIB;SAR 302503;TG-101348;TG 101348
- N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide USP/EP/BP
- N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzene-1-sulfonamide
- n-(1,1-dimethylethyl)-3-((5-methyl-2-((4-(2-(1-pyrrolidinyl)...
- Fedratinib D9
- 2H9]-Fedratinib
- TG101348 Fedratinib SAR302503 TG-101348
- Apoptosis,SAR-302503,STAT5,Inhibitor,Janus kinase,phosphorylation,FLT3,myeloproliferative,JAK2V617F,orally,SAR302503,inhibit,Fedratinib,anti-proliferation,JAK2,TG 101348,TG101348,JAK,RET,anti-cancer
- Bazedoxifene Impurity 13
- 936091-26-8
- C27H36N6O3S
- Inhibitor
- Inhibitors
- JAK
- STAT
